icode SRL
The score of icode shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +3 % Total assets +1 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
icode's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 12 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jul 2025
- Year ended 31 Dec 2023filed on 13 Jun 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 23 Aug 2022
icode's financial analysis
- Solvency28.8%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of icode
icode's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0469.114.665
- VAT number
- BE0469114665
- Peppol
- Registered · 0208:0469114665 · as of 04 Nov 2026
- Legal form
- SRL
- Incorporated
- 31 Dec 1999
- Registered office
- 1457 Walhain
- Latest accounts
- 2025 · filed on 12 Jun 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
icode (SRL) has been based in Walhain since 1999, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 45,375 € and equity of 22,867 €; its revenue is not published. Its solvency stands at 28.8%, below the median of its sector (58.2%).
Companies similar to icode
Companies in the same business, of comparable size and area, outside its group.
- Pharmaplex Research and experimental development on natural sciences and engineering Wezembeek-Oppem · balance sheet 482,967 €
- Avalon Consulting Research and experimental development on natural sciences and engineering Lasne · balance sheet 153,629 €
- "Clinical & Quality Support" Research and experimental development on natural sciences and engineering Villers-la-Ville · balance sheet 67,856 €
- IuMeDa Research and experimental development on natural sciences and engineering Leuven · balance sheet 66,280 €
- KST R & D Research and experimental development on natural sciences and engineering Liège · balance sheet 65,816 €
- VirAdvice Research and experimental development on natural sciences and engineering Leuven · balance sheet 75,092 €
- Mixed Matrix Material Innovations Research and experimental development on natural sciences and engineering Wommelgem · balance sheet 107,675 €
- Green Patriotism Research and experimental development on natural sciences and engineering Mortsel · balance sheet 123,338 €
Frequently asked questions about icode
What is the revenue of icode?
icode files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of icode?
In Belgium, the VAT number is the company number prefixed with BE: BE0469114665 for icode, if the company is VAT-registered. Its company number (CBE) is 0469.114.665.
Where is the registered office of icode?
According to the CBE register, the registered office of icode is in 1457 Walhain.
What is the equity of icode?
At the close of the 2025 financial year, the equity of icode amounts to 22,867 €, a solvency of 28.8% of total assets.
Who manages icode?
The register lists 3 active mandates at icode. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of icode
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →